
Scotland Approves First Licensed Ophthalmic Bevacizumab for Vision-Threatening Eye Disease
In a major step forward for ophthalmic care, Scotland has officially approved the first licensed formulation of bevacizumab for treating wet age-related macular degeneration (wet AMD). The Scottish Medicines Consortium (SMC) has given the green light to Lytenava (bevacizumab gamma), developed by Outlook Therapeutics, marking a significant development for patients at risk of permanent vision loss. A Game-Changer for Wet AMD Treatment Lytenava is the first and only licensed ophthalmic version of bevacizumab approved for wet AMD use in both the European Union and the United Kingdom. While bevacizumab has long been used off-label in ophthalmology, this is the first…